466 related articles for article (PubMed ID: 10193608)
1. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
Hernandez I; Soderlund D; Espinosa-de-los-Monteros AL; Ochoa R; Zarate A; Mercado M
J Neurosurg; 1999 Apr; 90(4):647-50. PubMed ID: 10193608
[TBL] [Abstract][Full Text] [Related]
2. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone binding protein and growth hormone availability in acromegalic patients treated with long-acting octreotide (Sandostatin-LAR).
Fisker S; Kaal A; Montini M; Pedroncelli A; Pagani G; Orskov H
Eur J Endocrinol; 1997 Jan; 136(1):61-6. PubMed ID: 9037128
[TBL] [Abstract][Full Text] [Related]
4. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
[TBL] [Abstract][Full Text] [Related]
5. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
6. [Lowered ghrelin levels in acromegaly—normalization after treatment].
Kozakowski J; Rabijewski M; Zgliczyński W
Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
[TBL] [Abstract][Full Text] [Related]
8. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels.
Lindsay JR; McConnell EM; Hunter SJ; McCance DR; Sheridan B; Atkinson AB
Pituitary; 2004; 7(3):139-144. PubMed ID: 16328564
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
10. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy.
Freda PU; Reyes CM; Conwell IM; Sundeen RE; Wardlaw SL
J Clin Endocrinol Metab; 2003 May; 88(5):2037-44. PubMed ID: 12727951
[TBL] [Abstract][Full Text] [Related]
11. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
[TBL] [Abstract][Full Text] [Related]
12. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.
Feelders RA; Bidlingmaier M; Strasburger CJ; Janssen JA; Uitterlinden P; Hofland LJ; Lamberts SW; van der Lely AJ; de Herder WW
J Clin Endocrinol Metab; 2005 Dec; 90(12):6480-9. PubMed ID: 16159936
[TBL] [Abstract][Full Text] [Related]
13. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly.
Biermasz NR; van Dulken H; Roelfsema F
J Clin Endocrinol Metab; 2000 Dec; 85(12):4596-602. PubMed ID: 11134114
[TBL] [Abstract][Full Text] [Related]
14. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
15. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
16. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly.
Grinspoon S; Clemmons D; Swearingen B; Klibanski A
J Clin Endocrinol Metab; 1995 Mar; 80(3):927-32. PubMed ID: 7533774
[TBL] [Abstract][Full Text] [Related]
17. Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients.
Laursen T; Møller J; Fisker S; Jorgensen JO; Christiansen JS
Growth Horm IGF Res; 1999 Dec; 9(6):451-7. PubMed ID: 10629166
[TBL] [Abstract][Full Text] [Related]
18. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
[TBL] [Abstract][Full Text] [Related]
19. High affinity growth hormone binding protein in plasma of patients with acromegaly and the effect of octreotide treatment.
Roelen CA; Donker GH; Thijssen JH; Koppeschaar HP; Blankenstein MA
Clin Endocrinol (Oxf); 1992 Oct; 37(4):373-8. PubMed ID: 1483295
[TBL] [Abstract][Full Text] [Related]
20. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
